Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sequential CD19 and CD22 CAR-T in Pediatric r/r B-ALL
NCT04340154Phase 2Terminated
- Sponsor
- Beijing Boren Hospital
- Start
- May 2020
- Primary completion
- May 2024
- Modality
- CAR-T Cells
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of autologous anti-CD19 CAR-T cells in B cell acute lymphoblastic leukemia (B-ALL), sponsored by Beijing Boren Hospital. Primary endpoint: Objective Response Rate at 3 months. Started May 2020; status: terminated.
02
Drugs
autologous anti-CD19 CAR-T cells
03
Conditions
B cell acute lymphoblastic leukemia (B-ALL)
Beyond the preview
Go deeper on NCT04340154.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04340154.